CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Enhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles

Koo, Jain, Shin, Yuseon, Jeon, Hyewon, Cheong, Jaehyun, Cho, Seongmin, Park, Chanho, Song, Ee Chan, Ramsey, Jacob D., Lim, Chaemin, Oh, Kyung Taek·2025·Journal of Controlled Release
DOI 10.1016/j.jconrel.2024.12.058
Open this paper in CoChat — free account

Abstract

Glioblastoma multiforme (GBM) is a devastating primary tumor of the central nervous system with a significantly poor prognosis. The primary challenge in treating GBM lies in the restrictive nature of the blood-brain barrier (BBB), impeding effective drug delivery to the brain. In this study, intranasal polymeric micelles encapsulating a quercetin-etoposide combination were developed to induce synergistic apoptotic effects and enhance direct drug delivery to the brain. However, the in vivo anticancer efficacy of the unmodified micelle formulation via intranasal administration remains limited. Therefore, this aims to investigate the enhancement of the formulation by conjugating the micelles with a novel and highly potent cell-penetrating peptide (CPP), RMMR1, identified using the intra-dermal delivery technology platform developed by REMEDI Co., Ltd. This modification seeks to enhance the brain-targeting capability of the micelles. The CPP-modified micelles encapsulating the quercetin-etoposide combination (CM(QE)) demonstrated superior in vivo brain-delivery efficiency and enhanced cellular uptake after intranasal administration. Furthermore, animal studies showed significant tumor reduction and increased survival rates, with no significant changes in body weight observed. These findings suggest that intranasal administration of CM(QE) holds promise as a significant advancement in chemotherapy for GBM.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2024.12.058

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 65

  1. Nozhat, 2023, Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery, Biomater. Sci., 11, 4094, 10.1039/D2BM01996E · DOI
  2. Shergalis, 2018, Current challenges and opportunities in treating glioblastoma, Pharmacol. Rev., 70, 412, 10.1124/pr.117.014944 · DOI
  3. Fisher, 2021, Current FDA-approved therapies for high-grade malignant gliomas, Biomedicines, 9, 324, 10.3390/biomedicines9030324 · DOI
  4. Olivier, 2021, Drug resistance in glioblastoma: the two faces of oxidative stress, Front. Mol. Biosci., 7, 10.3389/fmolb.2020.620677 · DOI
  5. Rong, 2022, Emerging therapies for glioblastoma: current state and future directions, J. Exp. Clin. Cancer Res., 41, 1, 10.1186/s13046-022-02349-7 · DOI
  6. Li, 2023, Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179, Research Square
  7. Hegde, 2022, Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches, J. Pharm. Investig., 52, 1, 10.1007/s40005-021-00548-6 · DOI
  8. Lee, 2023, Subcutaneous injection sites impact brain uptake of blood-brain barrier impermeable paclitaxel, J. Pharm. Investig., 53, 845, 10.1007/s40005-023-00634-x · DOI
  9. Arvanitis, 2020, The blood-brain barrier and blood-tumour barrier in brain Tumours and metastases, Nat. Rev. Cancer, 20, 26, 10.1038/s41568-019-0205-x · DOI
  10. Lim, 2023, Nanomedicine approaches for medulloblastoma therapy, J. Pharm. Investig., 53, 213, 10.1007/s40005-022-00597-5 · DOI
  11. Liu, 2022, Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor, Adv. Drug Deliv. Rev., 191, 10.1016/j.addr.2022.114619 · DOI
  12. Agrawal, 2018, Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs, J. Control. Release, 281, 139, 10.1016/j.jconrel.2018.05.011 · DOI · Paper page
  13. Koo, 2024, Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations, Int. J. Nanomedicine, 1767–1807
  14. Jeong, 2023, Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors, J. Pharm. Investig., 53, 119, 10.1007/s40005-022-00589-5 · DOI
  15. Cox, 2023, The role of the efflux transporter, P-glycoprotein, at the blood–brain barrier in drug discovery, Biopharm. Drug Dispos., 44, 113, 10.1002/bdd.2331 · DOI
  16. Chai, 2022, Regulation of P-glycoprotein in the brain, Int. J. Mol. Sci., 23, 14667, 10.3390/ijms232314667 · DOI
  17. Pathan, 2021, Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier, J. Control. Release, 335, 398, 10.1016/j.jconrel.2021.05.046 · DOI
  18. Jung, 2024, Development of core-shell structured nanoparticle for sequential release of tariquidar and docetaxel to overcome multi drug-resistant cancer, J. Pharm. Investig., 54, 61, 10.1007/s40005-023-00645-8 · DOI
  19. Karthika, 2022, Multidrug resistance of cancer cells and the vital role of P-glycoprotein, Life, 12, 897, 10.3390/life12060897 · DOI
  20. Shingaki, 2011, Nasal delivery of P-Gp substrates to the brain through the nose-brain pathway, Drug Metab. Pharmacokinet., 26, 248, 10.2133/dmpk.DMPK-10-RG-108 · DOI
  21. Anand, 2014, Drug transporters in the nasal epithelium: an overview of strategies in targeted drug delivery, Future Med. Chem., 6, 1381, 10.4155/fmc.14.77 · DOI
  22. Dolberg, 2016, Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells, Int. J. Pharm., 508, 22, 10.1016/j.ijpharm.2016.05.010 · DOI
  23. Kandimalla, 2005, Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae, Pharm. Res., 22, 1121, 10.1007/s11095-005-5420-3 · DOI
  24. Graff, 2005, Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation, Pharm. Res., 22, 235, 10.1007/s11095-004-1191-5 · DOI
  25. Hassanzadeganroudsari, 2020, Targeted nano-drug delivery system for glioblastoma therapy: in vitro and in vivo study, J. Drug Deliv. Technol., 60, 102039, 10.1016/j.jddst.2020.102039 · DOI
  26. Kadari, 2018, Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy, Eur. J. Pharm. Sci., 132, 168
  27. Ebrahimi Shahmabadi, 2014, Efficacy of cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma, Tumour Biol., 35, 4799, 10.1007/s13277-014-1630-9 · DOI
  28. Lim, 2022, Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-Seq–guided combination with sapanisertib, Sci. Adv., 8, 10.1126/sciadv.abl5838 · DOI
  29. Salaroglio, 2019, Validation of thiosemicarbazone compounds as P-glycoprotein inhibitors in human primary brain-blood barrier and glioblastoma stem cells, Mol. Pharm., 16, 3361, 10.1021/acs.molpharmaceut.9b00018 · DOI
  30. Sim, 2016, Nanomedicines for oral administration based on diverse nanoplatform, J. Pharm. Investig., 46, 351, 10.1007/s40005-016-0255-y · DOI
  31. Lim, 2022, Drug-dependent morphological transitions in spherical and worm-like polymeric micelles define stability and pharmacological performance of micellar drugs, Small, 18, 2103552, 10.1002/smll.202103552 · DOI
  32. Lim, 2023, High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer, Nano Today, 51, 10.1016/j.nantod.2023.101884 · DOI
  33. Singh, 2022, Quercetin acts as a P-Gp modulator via impeding signal transduction from nucleotide-binding domain to transmembrane domain, J. Biomol. Struct. Dyn., 40, 4507, 10.1080/07391102.2020.1858966 · DOI
  34. Mohana, 2016, Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer, Mol. Biosyst., 12, 2458, 10.1039/C6MB00187D · DOI
  35. Rauf, 2018, Anticancer potential of quercetin: a comprehensive review, Phytother. Res., 32, 2109, 10.1002/ptr.6155 · DOI
  36. Liu, 2017, Effects of quercetin on proliferation and migration of human glioblastoma U251 cells, Biomed. Pharmacother., 92, 33, 10.1016/j.biopha.2017.05.044 · DOI
  37. Shin, 2023, RNA-Seq-guided triple-combination nano-system of gold nanocluster, quercetin, and docetaxel for ultimate synergistic photothermal-chemotherapy against MDR tumor, Nano Today, 50, 10.1016/j.nantod.2023.101862 · DOI
  38. Hoang, 2017, Characterization of a triblock copolymer, poly(ethylene glycol)-polylactide-poly (ethylene glycol), with different structures for anticancer drug delivery applications, Polym. Bull., 74, 1595, 10.1007/s00289-016-1791-3 · DOI
  39. Mayer, 2019, Targeting specific membranes with an azide derivative of the pore-forming peptide ceratotoxin a, Biochim. Biophys. Acta Biomembr., 1861, 10.1016/j.bbamem.2019.07.011 · DOI
  40. Lee, 2013, Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells, Mol. Pharm., 10, 2323, 10.1021/mp300668e · DOI
  41. Gutmann, 1999, Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake, Pharm. Res., 16, 402, 10.1023/A:1018825819249 · DOI
  42. Netsomboon, 2016, Novel in vitro transport method for screening the reversibility of P-glycoprotein inhibitors, Eur. J. Pharm. Biopharm., 100, 9, 10.1016/j.ejpb.2015.11.019 · DOI
  43. Tang, 2016, Prediction of cell-penetrating peptides with feature selection techniques, Biochem. Biophys. Res. Commun., 477, 150, 10.1016/j.bbrc.2016.06.035 · DOI
  44. Sanders, 2011, Prediction of cell penetrating peptides by support vector machines, PLoS Comput. Biol., 7, 10.1371/journal.pcbi.1002101 · DOI
  45. Tangsangasaksri, 2016, siRNA-loaded polyion complex micelle decorated with charge-conversional polymer tuned to undergo stepwise response to intra-tumoral and intra-endosomal pHs for exerting enhanced RNAi efficacy, Biomacromolecules, 17, 246, 10.1021/acs.biomac.5b01334 · DOI
  46. Teo, 2017, pH and redox dual-responsive biodegradable polymeric micelles with high drug loading for effective anticancer drug delivery, Nanomed.: Nanotechnol., Biol. Med., 13, 431, 10.1016/j.nano.2016.09.016 · DOI
  47. Fathi Karkan, 2023, Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: a comprehensive review, Eur. J. Med. Chem., 259, 10.1016/j.ejmech.2023.115676 · DOI
  48. Mehta, 2018, Topoisomerase II poisons for glioblastoma: existing challenges and opportunities to personalize therapy, Front. Neurol., 9, 459, 10.3389/fneur.2018.00459 · DOI
  49. Franceschi, 2004, Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma, Br. J. Cancer, 91, 1038, 10.1038/sj.bjc.6602105 · DOI
  50. Kesari, 2007, Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults, Neuro-Oncol., 9, 354, 10.1215/15228517-2007-006 · DOI
  51. Aoki, 2010, Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme, J. Neurosurg., 112, 50, 10.3171/2009.5.JNS081738 · DOI
  52. Reardon, 2009, Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study, Br. J. Cancer, 101, 1986, 10.1038/sj.bjc.6605412 · DOI
  53. Pires, 2018, Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies, J. Control. Release, 270, 89, 10.1016/j.jconrel.2017.11.047 · DOI · Paper page
  54. Hada, 2017, Nose-to-brain transport of imatinib mesylate: a pharmacokinetic evaluation, Eur. J. Pharm. Sci., 102, 46, 10.1016/j.ejps.2017.02.032 · DOI
  55. Biswas, 2022, A comprehensive analysis and anti-cancer activities of quercetin in ROS-mediated cancer and cancer stem cells, Int. J. Mol. Sci., 23, 11746, 10.3390/ijms231911746 · DOI
  56. Shendge, 2021, The natural flavones, acacetin and apigenin, induce Cdk-cyclin mediated G2/M phase arrest and trigger ROS-mediated apoptosis in glioblastoma cells, Mol. Biol. Rep., 48, 539, 10.1007/s11033-020-06087-x · DOI
  57. Vlatkovic, 2022, Targeting cell cycle checkpoint kinases to overcome intrinsic radioresistance in brain tumor cells, Cancers, 14, 701, 10.3390/cancers14030701 · DOI
  58. Li, 2024, Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer, Cell. Mol. Biol. Lett., 29, 58, 10.1186/s11658-024-00578-6 · DOI
  59. Lu, 2020, Self-assembled micelles prepared from bio-based hydroxypropyl methyl cellulose and polylactide amphiphilic block copolymers for anti-tumor drug release, Int. J. Biol. Macromol., 154, 39, 10.1016/j.ijbiomac.2020.03.094 · DOI
  60. Kalinova, 2022, Functional polyion complex micelles for potential targeted hydrophobic drug delivery, Molecules, 27, 2178, 10.3390/molecules27072178 · DOI
  61. Wang, 2021, Biocompatibility, drug REelease, and anti-tumor effect of pH-sensitive micelles prepared from poly (2-ethyl-2-oxazoline)-poly (DL-lactide) block copolymers, Polym. Advan. Technol, 32, 4142, 10.1002/pat.5423 · DOI
  62. Kanazawa, 2014, Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles, Mol. Pharm., 11, 1471, 10.1021/mp400644e · DOI
  63. Yang, 2022, Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy, J. Control. Release, 342, 66, 10.1016/j.jconrel.2021.12.034 · DOI
  64. Alabsi, 2022, Nose-to-brain delivery of therapeutic peptides as nasal aerosols, Pharmaceutics, 14, 1870, 10.3390/pharmaceutics14091870 · DOI
  65. Elmowafy, 2023, Polysaccharide-based platforms for nasal delivery: design, features, and perspectives, J. Pharm. Investig., 53, 571, 10.1007/s40005-023-00626-x · DOI

Cited by

Sorted by citations

See all 23

Metadata

Authors
Koo, J., Shin, Y., Jeon, H., Cheong, J., Cho, S., Park, C., Song, E. C., Ramsey, J. D., Lim, C., & Oh, K. T.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2025-02
Volume
378
Pages
997-1012
ISSN
0168-3659
DOI
10.1016/j.jconrel.2024.12.058
Cited by
23
References
2
Language
en
Licence
Funders
  • CHA University (CHA-202301130001)
  • Korea Ministry of Science and ICT (2021R1A2C2008519, 2022R1C1C2002949, 2022R1A5A6000760)
  • National Research Foundation of Korea
  • Small and Medium Business Administration (S3209979)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review